Actionable driver gene alterations in early-stage non-small cell lung cancer: a review
Therapeutic Advances in Medical Oncology
Published online on January 17, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Early-stage (I–III) non-small cell lung cancer (NSCLC) can harbor oncogenic driver mutations that have critical implications for patient management and outcomes. Historically, molecular testing in resected NSCLC was limited, often focusing only onEGFR...
Early-stage (I–III) non-small cell lung cancer (NSCLC) can harbor oncogenic driver mutations that have critical implications for patient management and outcomes. Historically, molecular testing in resected NSCLC was limited, often focusing only onEGFR...